Technology

Edesa Biotech

$5.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (+5.17%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Edesa Biotech and other stocks, options, and ETFs commission-free!

About EDSA

Edesa Biotech, Inc. Common Shares, also called Edesa Biotech, is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded on June 12, 2007 and is headquartered in Markham, Canada. The listed name for EDSA is Edesa Biotech, Inc. Common Shares.

CEO
Pardeep Nijhawan
Employees
12
Headquarters
Markham, Ontario
Founded
2007
Market Cap
54.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
72.41K
High Today
$5.10
Low Today
$4.85
Open Price
$4.92
Volume
78.41K
52 Week High
$19.10
52 Week Low
$1.58

Collections

EDSA Earnings

-$0.22
-$0.15
-$0.07
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Feb 28, Pre-Market

You May Also Like

CHIS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure